Infectious diseases

Freshpet Voluntarily Recalls One Lot of Freshpet® Select Small Dog Bite Size Beef & Egg Recipe Dog Food Due to Potential Salmonella Contamination

Infectious diseases, Medical specialties, Neglected tropical diseases, Tropical diseases, Clinical medicine, Gram-negative bacteria, Pathogenic bacteria, Salmonella, Zoonoses

Saturday, June 12, 2021 - 6:51pm

BETHLEHAM, Pa., June 12, 2021 /PRNewswire/ --Freshpet Inc. is announcing a voluntary recall ofa single lot ofFreshpet SelectSmallDogBiteSizeBeef&EggRecipe Dog Food (1 LB bags), with Sell by Date 10/30/2021, due to potential contamination with Salmonella.

Key Points:

BETHLEHAM, Pa., June 12, 2021 /PRNewswire/ --Freshpet Inc. is announcing a voluntary recall ofa single lot ofFreshpet SelectSmallDogBiteSizeBeef&EggRecipe Dog Food (1 LB bags), with Sell by Date 10/30/2021, due to potential contamination with Salmonella.
Our Freshpet Team had designated this single lot for destruction, but it was inadvertently shipped to retailers in limited geographic markets between June 7 and June 10, 2021.
Rarely,Salmonellacan result in more serious ailments, including arterial infections, endocarditis, arthritis, muscle pain, eye irritation, and urinary tract symptoms.
Sell by Date, along with UPC code and lot code, can be found on the bottom and back of each bag.

Tampa General Hospital's Infection Prevention Team Receives 2021 APIC Heroes Award for Outstanding COVID-19 Response

Epidemiology, Infectious diseases, Health sciences, Association for Professionals in Infection Control and Epidemiology, Infection prevention and control, Infection, Health, APIC, Medicine

Friday, June 11, 2021 - 6:07pm

TAMPA, fla., June 11, 2021 /PRNewswire/ -- Tampa General Hospital announced today that its Infection Prevention Team received the 2021 Heroes in Infection Prevention Award in the Infection Prevention and Control Operations category from the Association for Professionals in Infection Control and Epidemiology (APIC) .

Key Points:

TAMPA, fla., June 11, 2021 /PRNewswire/ -- Tampa General Hospital announced today that its Infection Prevention Team received the 2021 Heroes in Infection Prevention Award in the Infection Prevention and Control Operations category from the Association for Professionals in Infection Control and Epidemiology (APIC) .
In addition to the team award, Benjamin D. Galvan, infection preventionist at Tampa General, was also recognized as an emerging leader for 2021.
Throughout the COVID-19 pandemic, Tampa General's infection prevention team provided:
Training on personal protective equipment (PPE) for the clinical teams' safety.
"The Heroes award is especially meaningful because it recognizes the commitment shown by the infection protection team during extraordinarily challenging circumstances," said Kimberly Atrubin, director of infection prevention for Tampa General.

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering

Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Initial public offering, Prospectus, U.S. Securities and Exchange Commission, Financial economics, Finance, Registration statement, Money, Stock market, Financial markets, Corporate finance, Red herring prospectus

Friday, June 11, 2021 - 4:49pm

Additionally, the Company has granted the underwriter a 30-day option to purchase up to 210,000 additional shares to cover over-allotments.

Key Points:

Additionally, the Company has granted the underwriter a 30-day option to purchase up to 210,000 additional shares to cover over-allotments.
Kingswood Capital Markets, division of Benchmark Investments, LLC acted as sole book-running manager for the offering.
The shares of common stock described above were offered by CEL-SCI pursuant to a "shelf" registration statement on Form S-3 (File No.
A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering was filed with the SEC.

Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia

Medical Supplies, Health, Infectious diseases, General Health, Pharmaceutical, Biotechnology, COVID-19 vaccines, Clinical trials, RNA vaccines, Medical research, Health sciences, Medicine, Health, Moderna COVID-19 vaccine, Tabuk, Moderna, COVID-19 vaccine

Friday, June 11, 2021 - 1:30pm

Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia.

Key Points:

Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia.
We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia, said Stphane Bancel, Chief Executive Officer of Moderna.
We welcome the opportunity to work with Tabuk Pharmaceuticals to bring the Moderna COVID-19 and potentially other Moderna mRNA products to Saudi Arabia in the future, said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna.
Established in Saudi Arabia in 1994, Tabuk Pharmaceuticals is a leading regional pharmaceutical in the Middle East and North Africa (MENA).

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

Oncology, Health, Medical devices, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Branches of biology, Clinical medicine, Medical tests, Biotechnology, Molecular biology, Immunologic tests, Chromatography, Rapid antigen test, Lateral flow test, Severe acute respiratory syndrome, Polymerase chain reaction

Friday, June 11, 2021 - 12:25pm

Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.

Key Points:

Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.
The clinical data for Avactas AffiDX SARS-CoV-2 antigen lateral flow test reported 20 April 2021, demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct
The product registration by a Competent Authority in the EU allows the Company to sell the product in the EU for professional use.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: We are delighted to receive confirmation of the registration of the AffiDX SARS-CoV-2 antigen test in the EU.

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World

Environment, Research, Infectious diseases, Fitness & Nutrition, Public policy, Government, Health, General Health, Other Science, Science, Behavioural Insights Team, Cabinet Office, Nudge theory, Medical specialties, Social distancing, Health sciences, Medicine

Friday, June 11, 2021 - 9:15am

The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic.

Key Points:

The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic.
Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing.
Ed Bradon, Director of Home Affairs, Security, and International Development at the United Kingdom Behavioural Insights Team offered insights from an intervention programme in New Zealand.
Sabrina Ng, Deputy Director of the Behavioural Insights Unit, Singaporean Ministry of Home Affairs, brings over seven years of experience in behavioural science from her work in the Ministry.

AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares

Thursday, June 10, 2021 - 10:11pm

Proceeds from the sale were paid to the Selling Shareholders, and AbCellera did not receive any proceeds.

Key Points:

Proceeds from the sale were paid to the Selling Shareholders, and AbCellera did not receive any proceeds.
Following the sale and the allocation of shares for future charitable donations, Dr. Hansen remains AbCelleras largest shareholder with 54,354,330 common shares, representing approximately a 20% equity interest on an undiluted basis.
The Shares were sold by way of a private sale between individual Selling Shareholders and Buyers, who were already investors in AbCellera.
Following the sale, the Selling Shareholders retain approximately 89% of their total equity holdings, which represent approximately 30% of AbCelleras fully diluted shares.

U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C

Health, FDA, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Gilead Sciences, Health sciences, Chemistry, Combination drugs, Breakthrough therapy, Specialty drugs, Hepatitis C, Sofosbuvir, Velpatasvir, Protease inhibitor, Viral hepatitis

Thursday, June 10, 2021 - 10:00pm

The recommended dosage of Epclusa in children ages 3 years and older is based on weight.

Key Points:

The recommended dosage of Epclusa in children ages 3 years and older is based on weight.
Sofosbuvir/velpatasvir is the only protease inhibitor-free, pangenotypic HCV regimen approved for patients as young as 3 years of age.
Of the seven patients who did not achieve cure, all discontinued treatment within one to 20 days of starting treatment.
The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

Aegis Launches COVID-19 Testing Program for Schools

Thursday, June 10, 2021 - 7:10pm

to help keep schools open during the COVID-19 pandemic through pooled testing.

Key Points:

to help keep schools open during the COVID-19 pandemic through pooled testing.
This testing program was designed to be simple for schools to use while reducing costs and increasing access to testing.
to make ongoing testing easy for teachers and students, so schools can safely and confidently remain open.
Aegis tests and reports each pool, and follow-up testing is recommended for each student or staff in a positive pool.

Walgreens Continues to Boost COVID-19 Vaccination Access Across the Country

Infectious diseases, General Health, Pharmaceutical, Health, Companies, Walgreens, Health care, Boots, WBA, Pharmacies

Thursday, June 10, 2021 - 2:15pm

On Friday, June 11, 18 and 25, 4,000 Walgreens pharmacy locations will extend hours of operation for walk-in vaccinations.

Key Points:

On Friday, June 11, 18 and 25, 4,000 Walgreens pharmacy locations will extend hours of operation for walk-in vaccinations.
Individuals can visit Walgreens online store locator or call their local Walgreens to check for updated pharmacy hours of operation.
Additionally, Walgreens has more than 400 24-hour pharmacy locations across the country where individuals can receive a COVID-19 vaccine on a walk-in basis.
Walgreens ( www.walgreens.com ) is included in the United States segment of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), a global leader in retail pharmacy.